Pfizer's Elrexfio Receives Conditional NMPA Approval for Relapsed Multiple Myeloma
CompanyDrug

Pfizer’s Elrexfio Receives Conditional NMPA Approval for Relapsed Multiple Myeloma

MicroPort Scientific Corp. Reports 10% Revenue Growth and 58% Net Loss Decrease in 2024
Company

MicroPort Scientific Corp. Reports 10% Revenue Growth and 58% Net Loss Decrease in 2024

SonoScape Medical Corp. Wins First AI-Powered Prenatal Ultrasound Approval in China
CompanyMedical Device

SonoScape Medical Corp. Wins First AI-Powered Prenatal Ultrasound Approval in China

TYK Medicines Inc.'s TY-9591 Shows Superiority Over Osimertinib in EGFR Mutated Lung Cancer with Brain Metastasis
CompanyDrug

TYK Medicines Inc.’s TY-9591 Shows Superiority Over Osimertinib in EGFR Mutated Lung Cancer with Brain Metastasis

Anlong Biopharmaceutical and Sun-Novo Partner to Advance siRNA Technology in Cardiovascular Treatments
CompanyDeals

Anlong Biopharmaceutical and Sun-Novo Partner to Advance siRNA Technology in Cardiovascular Treatments

AIM Vaccine Co. Ltd Receives NMPA Approval for Human Diploid Rabies Vaccine Trial
CompanyDrug

AIM Vaccine Co. Ltd Receives NMPA Approval for Human Diploid Rabies Vaccine Trial

NewCo Model: China's Innovative Drug Companies' New Transaction Mode in Capital Winter
CompanyDeals

NewCo Model: China’s Innovative Drug Companies’ New Transaction Mode in Capital Winter

Hangzhou Chance Pharmaceuticals Secures New Funding for Inhalation Powder Aerosol Development
Company

Hangzhou Chance Pharmaceuticals Secures New Funding for Inhalation Powder Aerosol Development

Sino Biopharmaceutical Licenses Nanjing Delova's QP001 for Mainland China Rights
CompanyDeals

Sino Biopharmaceutical Licenses Nanjing Delova’s QP001 for Mainland China Rights

Fosun Pharmaceutical's Foritinib Accepted for Review by China's NMPA for NSCLC Treatment
CompanyDrug

Fosun Pharmaceutical’s Foritinib Accepted for Review by China’s NMPA for NSCLC Treatment

Everest Medicines Begins Clinical Trial for Personalized mRNA Cancer Vaccine EVM16
CompanyDrug

Everest Medicines Begins Clinical Trial for Personalized mRNA Cancer Vaccine EVM16

Sinocelltech Group Receives NMPA Approval for SCTT11 Clinical Study in Thyroid Eye Disease
CompanyDrug

Sinocelltech Group Receives NMPA Approval for SCTT11 Clinical Study in Thyroid Eye Disease